AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

A Method for Manufacturing Potent Dendritic Cells

Technology Benefits: • Generation of a potent DC vaccine for treatment of cancer or infectious disease.• Generates DCs with greater potency than those produced by currently available methods.o Generation of potency is achieved through biological stimuli, circumventing the need for genetic vectors or prolonged cell selection.

Detailed Technology Description: Researchers at UCLA have developed a novel method for inducing dendritic cells (DCs) from monocytes. Compared to current methods, this innovation generates DCs with greater potency as antigen presenting cells for the activation of T cells. These potent DCs could be infused into cancer or infectious disease patients as part of a vaccine to enhance T cell activation.

Supplementary Information: Patent Number: WO2012142597A1
Application Number: WO2012US33811A
Inventor: MODLIN, Robert Lazarus | SCHENK, Mirjam
Priority Date: 15 Apr 2011
Priority Number: WO2012142597A1
Application Date: 16 Apr 2012
Publication Date: 18 Oct 2012
IPC Current: C12N0005071
Assignee Applicant: The Regents of the University of California
Title: A METHOD FOR GENERATING POTENT DENDRITIC CELLS | PROCÉDÉ POUR LA GÉNÉRATION DE CELLULES DENDRITIQUES PUISSANTES
Usefulness: A METHOD FOR GENERATING POTENT DENDRITIC CELLS | PROCÉDÉ POUR LA GÉNÉRATION DE CELLULES DENDRITIQUES PUISSANTES
Summary: The method is useful for inducing dendritic cell differentiation from a mammalian precursor cell (claimed).

Industry: Biomedical

Sub Category: DNA/Gene Engineering

Application No.: 9273284

Others

Additional Technologies by these Inventors

Polycytotoxic T Cells

Tech ID/UC Case

22306/2011-562-0

Related Cases

2011-562-0

*Abstract: Dendritic cells (DCs) are antigen-presenting cells that play a critical role in the regulation of adaptive immune responses. They instruct and activate T cells and are therefore crucial for establishing immunological memory. Immense research effort is being expended to create dendritic cell vaccines, which may potentially prime a patients’ immune system against infectious pathogens or cancer cells. Currently, there are several clinical trials underway that use in vitro-induced DCs to induce immunity to antigens against breast cancer, lung cancer, melanoma, prostate, and renal cell cancers. Novel methods to generate DCs with an increased potency to stimulate immunity will be a significant advance in treating patients with cancer or infectious disease.

*IP Issue Date: Mar 1, 2016

*Principal Investigator: Name: Robert Modlin
Department:

Name: Mirjam Schenk
Department:

Country/Region: USA

For more information, please click Here